


## **Technology Advisory Committee C Interests Register**


Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line

chemoimmunotherapy [ID1684] Publication Date: 07/06/2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Stella O'Brien	Committee Member	Personal	Ms O'Brien is a member of the Genetics Alliance UK PPIE Working Group on ATMPs affiliated with CATAPULT cell and gene therapy to encourage the integration of PPIE throughout the research cycle from the earliest stages and onwards. CATAPULT is a network of not-for profit, independent centres which connect businesses with the UK's research and academic communities. Although CART therapies are an example of ATMPs, she has not contributed to work on CART therapies with this group.	N/A	17/10/2022	N/A	It was agreed her declaration would not prevent Ms O'Brien from participating in discussions on this appraisal.
Dr Richard Nicholas	Committee Member	Direct financial	Dr Nicholas has attended paid advisory boards with Roche in an unrelated disease area (Multiple Sclerosis).	N/A	26/01/2023	N/A	It was agreed that his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal



Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Sridhar Chaganti	Clinical expert	Direct financial	Dr Chaganti has received honoraria for consultancy, advisory boards, speaker fees or meeting support from Kite/Gilead, Novartis, Celgene/BMS, Incyte, Roche, Takeda, Atarabio and Orion Pharma.	N/A	28/01/2022	N/A	It was agreed his declarations would not prevent Dr Chaganti from providing expert advice to the committee.
Dr Andrew McMillan	Clinical expert	Direct financial	Dr McMillan has worked indirectly for NHS England as Chair of the National CAR-T cell Clinical Panel for Lymphoma and has received honoraria and travel sponsorship from Roche and Amgen which have other non-CAR-T competing products for the treatment of Lymphoma.	N/A	08/02/2022	N/A	It was agreed his declarations would not prevent Dr McMillan from providing expert advice to the committee
Robert Cross	Patient expert	Indirect financial	Mr Cross' nominating organisation Anthony Nolan has received funding from Kite/Gilead to conduct a CAR-T patient experience study and for attendance at an advisory board and an online seminar.	N/A	16/08/2022	N/A	It was agreed his declarations would not prevent Mr Cross from providing expert advice to the committee.
Rebecca Hallam	Patient expert	Direct & indirect financial	Mrs Hallam's nominating organisation Anthony Nolan has received funding from Kite/Gilead to conduct a CAR-T patient experience	N/A	16/08/2022	N/A	It was agreed her declarations would not prevent Mrs Hallam from providing expert advice to the committee.



Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			study and for attendance at an advisory board and an online seminar.				
			Mrs Hallam has received payment for presenting the role of ambulatory care in the delivery of CAR-T cell therapy for Novartis at a study evening in November 2021 and payment to review the BMT information in the booklet for Cancer Research UK.				